Hemorrhagic transformation within 36 hours of a cerebral infarct: Relationships with early clinical deterioration and 3-month outcome in the European Cooperative Acute Stroke Study I (ECASS I) cohort

Stroke

Volumn 30, Issue 11, 1999, Pages 2280-2284

  Fiorelli, Marco ^a,g   Bastianello, Stefano ^a   Von Kummer, Rüdiger ^b   Del Zoppo, Gregory J ^c   Larrue, Vincent ^d   Lesaffre, Emmanuel ^e   Ringleb, Arthur P ^f   Lorenzano, Svetlana ^a   Manelfe, Claude ^d   Bozzao, Luigi ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

^d UNIVERSITÉ DE TOULOUSE   (France)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f UNIVERSITY OF HEIDELBERG   (Germany)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Hemorrhagic; Prognosis; Stroke; Tissue plasminogen activator

Indexed keywords

ALTEPLASE;

ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA BASE; DISABILITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MORTALITY; OUTCOMES RESEARCH; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

EID: 0032724534     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.STR.30.11.2280     Document Type: Article

References (23)

1. Hornig CR, Dorndorf W, Agnoli AL. Hemorrhagic cerebral infarction: a prospective study. Stroke. 1986;17:179-185.
2. Bozzao L, Angeloni U, Bastianello S, Fantozzi LM, Pierallini A, Fieschi C. Early angiographic and CT findings in patients with hemorrhagic infarction in the distribution of the middle cerebral artery. AJNR Am J Neuroradiol. 1991;12:1115-1121.
3. Moulin T, Crépin-Leblond T, Chopard JL, Bogousslavsky J. Hemorrhagic infarcts. Eur Neurol. 1994;34:64-77.
4. Toni D, Fiorelli M, Bastianello S, Sacchetti ML, Sette G, Argentino C, Montinaro E, Bozzao L. Hemorrhagic transformation of brain infarct: predictability in the first 5 hours from stroke onset and influence on clinical outcome. Neurology. 1996;46:341-345.
5. Pessin MS, Teal PA, Caplan LR. Hemorrhagic infarction: guilt by association? AJNR Am J Neuroradiol 1991;12:1123-1126.
6. del Zoppo GJ, Poeck K, Pessin MS, Wolpert SM, Furlan AJ, Ferbert A, Alberts MJ, Zivin JA, Wechsler L, Busse O, Greenlee R Jr, Brass L, Mohr JP, Feldmann E, Hacke W, Kase CS, Biller J, Gress D, Otis SM. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992;32:78-86.
7. Hacke W, Kaste M, Fieschi C, Toni D, Lesaffre E, von Kummer R, Boysen G, Bluhmki E, Hoxter G, Mahagne MH, Hennerici MG, for the ECASS Study Group. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA. 1995;274:1017-1025.
8. The NINDS rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
9. Hommel M, Boissel JP, Cornu C, Boutitie F, Lees KR, Besson G, Leys D, Amarenco P, Bogaert M, for the MAST Study Group. Termination of trial of streptokinase in severe acute ischemic stroke. Lancet. 1995; 345:57. Letter.
10. Multicenter Acute Stroke Trial-Italy (MAST-I) Group. Randomized controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischemic stroke. Lancet. 1995;346:1509-1514.
11. Donnan GA, Davies SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, Roseen D, Stewart-Wynne EG, Tuck RR. Trials of streptokinase in severe acute ischemic stroke. Lancet. 1995;354:578-579.
12. Hacke W, Kaste M, Fieschi C, von Kummer, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, Schneider D, Diez-Tejedor E, Trouillas P, for the Second European-Australasian Acute Stroke Study Investigators. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischemic stroke (ECASS II). Lancet. 1998;352:1245-1251.
13. Larrue V, von Kummer R, del Zoppo G, Bluhmki E. Hemorrhagic transformation in acute ischemic stroke. Stroke. 1997;28:957-960.
14. Pessin M, del Zoppo GJ, Estol C. Thrombolytic agents in the treatment of stroke. Clin Neuropharmacol. 1990;13:271-289.
15. Landis JR, Koch GG. The measurement of observer agreement in categorical data. Biometrics. 1977;33:159-174.
16. Brott TG, Haley EC, Levy DE, Barsan W, Broderick J, Sheppard GL, Spilker J, Kongable GL, Massey S, Reed R, Marler JR. Urgent therapy for stroke, part I: pilot study of tissue plasminogen activator administered within 90 minutes. Stroke. 1992;23:632-640.
17. Rankin J. Cerebral vascular accidents in patients over age of 60, II: prognosis. Scott Med J. 1957;2:200-215.
18. Dixon WJ, ed-in-chief. BMDP Statistical Software Manual. Berkeley: University of California Press; 1990.
19. Mori E, Yoneda Y, Tabuchi M, Yoshida T, Ohkawa S, Ohsumi Y, Kitano K, Tsutsumi A, Yamadori A. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology. 1992;42: 976-982.
20. Lyden PD, Zivin JA. Hemorrhagic transformation after cerebral ischemia: mechanisms and incidence. Cerebrovasc Brain Metab Rev. 1993;5:1-16.
21. Hamann GF, Okada Y, Fitridge R, del Zoppo GJ. Microvascular basal lamina antigens disappear during cerebral ischemia and reperfusion. Stroke. 1995;26:2120-2126.
22. Hamann GF, Okada Y, del Zoppo GJ. Hemorrhagic transformation and microvascular integrity during focal cerebral ischemia/reperfusion. J Cereb Blood Flow Metab. 1996;16:1373-1378.
23. The NINDS rt-PA Stroke Study Group. Intracerebral hemorrhage after intravenous rt-PA therapy for ischemic stroke. Stroke. 1997;28: 2109-2118.